KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Interest Expenses: 2010-2025

Historic Interest Expenses for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to $4.3 million.

  • Pacira BioSciences' Interest Expenses fell 8.74% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year increase of 19.36%. This contributed to the annual value of $16.6 million for FY2024, which is 18.40% down from last year.
  • Latest data reveals that Pacira BioSciences reported Interest Expenses of $4.3 million as of Q3 2025, which was down 8.86% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Interest Expenses ranged from a high of $11.0 million in Q4 2022 and a low of $3.3 million during Q1 2024.
  • Its 3-year average for Interest Expenses is $4.6 million, with a median of $4.3 million in 2025.
  • Per our database at Business Quant, Pacira BioSciences' Interest Expenses skyrocketed by 47.59% in 2021 and then tumbled by 69.31% in 2023.
  • Pacira BioSciences' Interest Expenses (Quarterly) stood at $10.4 million in 2021, then climbed by 5.93% to $11.0 million in 2022, then crashed by 69.31% to $3.4 million in 2023, then surged by 38.13% to $4.7 million in 2024, then dropped by 8.74% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, $4.7 million for Q2 2025, and $4.6 million during Q1 2025.